Concurrent onabotulinumtoxina treatment of cervical dystonia and concomitant migraine
Headache: The Journal of Head and Face Pain,  Clinical Article

Winner PK et al. – Concurrent treatment with onabotulinumtoxinA is effective and well tolerated in controlling the symptoms of cervical dystonia complicated by concurrent migraine.

Methods
  • An open–label pilot study was conducted for 7.5 months in patients at least 18 years old with primary cervical dystonia of moderate severity (baseline rating of at least 20 on the Toronto Western Spasmodic Torticollis Rating Scale) complicated by migraine headache meeting the International Classification of Headache Disorders–II criteria for migraines with or without aura.
  • Each patient received 2 cycles of treatment at Visit 3 (baseline) and Visit 6 (Day 90).
  • For cervical dystonia, each patient was injected with a maximum of 175 units.
  • At the same visit, a maximum of 125 units was also injected for migraine using a fixed–site, fixed–dose injection paradigm, with additional cervical dystonia injection–site treatment to a maximum dose of 300 units.
  • Patients were assessed following onabotulinumtoxinA injection and at follow–up on Visit 4 (Day 30), Visit 5 (Day 60), Visit 6 (Day 90), and at Visits 7, 8, and 9 (Days 120, 150, and 180).
  • The primary outcome measures for this study were change in Toronto Western Spasmodic Torticollis Rating Scale total score for cervical dystonia and frequency of headache episodes per 28–day period.
  • Migraine episodes were defined as at least 4 hours of sustained pain with no upper limit.
  • An episode was considered new if the patient was pain free for at least 24 hours.
  • Secondary study end points included number of headache days per month, headache intensity, headache disability (assessed using Headache Impact Test–6 and the Migraine Disability Assessment score scales), acute headache medication use, resource utilization, and allodynia pain.
  • Adverse events were reported.

Results
  • A total of 25 patients (24 women, mean age 50.5 years; mean age of disease onset 21.9 years) were enrolled in the study.
  • Patients experienced improvement in cervical dystonia symptoms with significant reductions from baseline in Toronto Western Spasmodic Torticollis Rating Scale scores at 30, 60, 90, 120, 150, and 180 days (–9.84 ± 8.49, –12.67 ± 8.22, –13.63 ± 7.27, –14.92 ± 7.05, –4.76 ± 6.97, –14.49 ± 6.14, respectively, P < .0001 at all time points from a baseline of 31.03 ± 3.61).
  • Changes from baseline were assessed using the t–test.
  • Reductions in the number of headache episodes from baseline on concurrent onabotulinumtoxinA treatment for coexistent chronic migraine did not attain significance.
  • However, patients experienced significant reductions from baseline in the number of headache days at 90, 120, and 180 days (–3.39 ± 6.78, P = .0289; –4.29 ± 7.94, P = .0194; –4.38 ± 7.99, P = .0178, respectively, from a baseline of 15.33 ± 6.76).
  • Changes from baseline were assessed using the t–test.
  • The change from baseline in Headache Impact Test–6 total scores was significant at 30, 60, 90, 150, and 180 days (3.21 ± 4.14, P = .0009; –3.04 ± 4.04, P = .0012; –2.41 ± 2.79, P = .0006; –2.59 ± 3.87, P = .0050; –3.09 ± 3.80, respectively, from a baseline of 22.68 ± 3.20).
  • Changes from baseline were assessed using the t–test.
  • The change from baseline in Migraine Disability Assessment was significant at 120, 150, and 180 days (–38.09 ± 47.87, P < .0001, Wilcoxon signed rank test; –16.91 ± 62.69, P = .0358, Wilcoxon signed rank test; ?23.73 ± 40.57, P = .0122, t–test, respectively, from a baseline of 56.68 ± 50.41).
  • There were no serious adverse events or treatment–related disc

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Neurology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Neurology Articles

1 Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, August 1, 2014    Clinical Article

2 Consumption of nuts and legumes and risk of stroke: a meta-analysis of prospective cohort studies Nutrition, Metabolism & Cardiovascular Diseases, July 28, 2014    Evidence Based Medicine    Clinical Article

3 Intracranial hemorrhage risk with the new oral anticoagulants: A systematic review and meta-analysis Journal of Neurology, September 2, 2014    Evidence Based Medicine    Review Article

4 Patent foramen ovale closure versus medical therapy for stroke prevention: meta analysis of randomized trials and review of heterogeneity in meta analyses Canadian Journal of Cardiology, August 7, 2014    Evidence Based Medicine    Review Article    Clinical Article

5 Occupational exposure to extremely low-frequency magnetic fields and brain tumor risks in the INTEROCC Study Cancer Epidemiology, Biomarkers & Prevention, September 9, 2014

6 Antiplatelet strategies for secondary prevention of stroke and TIA Current Atherosclerosis Reports, September 11, 2014    Review Article

7 Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES European Heart Journal, September 8, 2014    Clinical Article

8 Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin Stroke, August 14, 2014    Clinical Article

9 Trial of ORG 10172 in acute stroke treatment (TOAST) classification and vascular territory of ischemic stroke lesions diagnosed by diffusion-weighted imaging Full Text Journal of the American Heart Association, September 16, 2014    Free full text    Clinical Article

10 Antiepileptics in migraine prophylaxis: An updated Cochrane review Cephalalgia, August 14, 2014    Clinical Article

11 Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial European Heart Journal, September 17, 2014    Clinical Article

12 Initial 3-weeks’ apixaban versus dual-antiplatelet therapy (clopidogrel and aspirin) followed by clopidogrel alone in high-risk patients with acute non-disabling cerebrovascular events (adance): study protocol for a randomized controlled trial Clinical Drug Investigation, September 15, 2014    Clinical Article

13 Oral anticoagulants for stroke prevention in atrial fibrillation Current Problems in Cardiology, September 22, 2014    Review Article

14 Early deterioration after thrombolysis plus aspirin in acute stroke Stroke, September 26, 2014    Clinical Article

15 Coronary artery calcification, intima-media thickness, and ankle-brachial index are complementary stroke predictors Stroke, August 29, 2014    Clinical Article

16 Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study American Journal of Medicine, September 29, 2014    Clinical Article

17 Potassium intake and risk of stroke in women with hypertension and nonhypertension in the women’s health initiative Stroke, September 24, 2014    Clinical Article

18 Clinical trials in acute ischemic stroke CNS Drugs, September 4, 2014    Review Article

19 Vitamin D and sleep disorders Full Text Nature and Science of Sleep, August 13, 2014    Free full text    Clinical Article

20 Bleeding risk, physical functioning, and non-use of anticoagulation among patients with stroke and atrial fibrillation QJM: An International Journal of Medicine, September 19, 2014    Clinical Article

Indexed Journals in Neurology: Current Opinion in Neurology, Stroke, Seizure, Cephalgia, Brain Injurymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close